Researchers from A*STAR’s Institute of Molecular and Cell Biology (IMCB), and the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have identified a unique gene that may make it easier to predict both breast cancer relapses and responses to chemotherapy. The newly found biomarker could help physicians classify each breast cancer patient and customise a treatment regimen that is more effective.
Despite advancements in cancer treatment, breast cancer remains the most common cancer. Thirty percent of early breast cancer patients in the world experience relapse due to metastasis, or the spread of cancer cells to other organs in the body. Some patients may also not respond well to chemotherapy. The inability to forecast relapses or the effectiveness of chemotherapy has led to a pressing need to identify predictive markers, which doctors can use to tailor appropriate treatment for each breast cancer patient at an early stage.
DP103… will facilitate doctors in selecting suitable treatments for different cases of breast cancer…
Master Regulator
In a study published recently in the Journal of Clinical Investigation, a top-tier journal for discoveries in basic and clinical biomedical research, the team of scientists jointly led by Vinay Tergaonkar,PhD, Principal Investigator at IMCB and Alan Prem Kumar, PhD, Principal Associate at CSI Singapore and Assistant Professor at the Department of Pharmacology, NUS Yong Loo Lin School of Medicine, uncovered a gene, DP103, which is activated in metastatic breast cancer.
DP103, identified as as biomarker and metastasis-driving oncogene in human breast cancers acts as a master regulator. It expresses two sets of unfavourable proteins ? one of these, matrix metallopeptidase 9 (MMP9) – leads to metastasis and the other (NF-?B) causes patients to be unresponsive to chemotherapy. Consequently, doctors can predict the probability of metastasis by examining the levels of DP103 in breast cancer patients. The same gene could also be used to predict whether a patient would respond to chemotherapy.
“Doctors are unable to tell if a breast cancer patient will respond to chemotherapy until six months after the treatment has been prescribed. It is very worrisome as the ones who are not responsive to chemotherapy usually also suffer relapses due to metastasis. This DP103 gene that we found explains the link and will facilitate doctors in selecting suitable treatments for different cases of breast cancer,” Tergaonkar said.
In addition, the study revealed that reducing the levels of DP103 could contain the cancer, shrink the tumour and make patients more amenable to chemotherapy. All the findings in the study have been validated with samples of breast cancer patients from Singapore, Canada, China and the USA.
Therapeutic Target
“DP103 is a novel biomarker that could help doctors select appropriate treatments for breast cancer patients at an early stage. It is also a therapeutic target which could be explored further to develop drugs that suppress breast cancer growth, as well as metastasis,” Kumar noted, who first discovered DP103’s oncogene potential to drive breast cancer metastasis. Kumar is also the principal inventor to a patent application on this discovery and is currently looking into ways to regulate DP103 levels in a variety of cancer types at CSI Singapore.
For more information:
Shin EM, Sin Hay H, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, et al. DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J Clin Invest. 2014 Aug 1. pii: 73451. doi: 10.1172/JCI73451.[Article][PubMed]
Copyright ? 2014 Sunvalley Communication. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
